Oncolytics Biotech Wins FDA Fast Track for Colorectal Cancer Treatment
Oncolytics Biotech receives FDA Fast Track designation for pelareorep in treating KRAS-mutant colorectal cancer, showing promising survival improvements.
/ 904 items
#Healthcare↓
Hims Adds Cancer Detection Test to Labs Product
Hims & Hers partners with Grail to offer discounted Galleri cancer detection tests through its Labs subscription service, expanding beyond weight-loss treatments.
Boston Scientific Shares Drop Despite Strong Q4 as 2026 Outlook Disappoints
Boston Scientific (BSX) reports strong Q4 2025 earnings but shares fall over 10% on modest 2026 guidance. Revenue growth expected to slow to 10-11% from 15.8% in 2026.
Eli Lilly Crushes Forecasts on Weight-Loss Drug Boom
Eli Lilly (LLY) beats Q4 expectations and projects strong 2026 growth driven by surging demand for Zepbound and Mounjaro, outpacing rival Novo Nordisk.
Novo Nordisk Expects Sales Drop in 2026 Amid Rising Competition
Novo Nordisk forecasts 5-13% sales decline for 2026 as Ozempic and Wegovy face intense competition from Eli Lilly and generics, plus US drug pricing pressures.
Prelude Therapeutics Gets FDA Green Light for Groundbreaking Blood Cancer Treatment
Prelude Therapeutics receives FDA clearance to begin testing PRT12396, a targeted therapy for myeloproliferative neoplasms affecting thousands of patients.